Article

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma

2026-04-10

Abstract excerpt

<h4>Background</h4> Appendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. KRAS is the most commonly mutated gene in AA and a promising therapeutic target, but its preclinical and translational relevance in AA remains unclear. <h4>Methods</h4> We evaluated KRAS G12D –specific (MRTX1133) and pan-KRAS inhibitor (RMC-6236) in KRAS mut organoid and orthotopic PDX models of AA. Tumor-in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4a039e0f-39f0-59f2-b077-eb7cd3ea2696
DOI: 10.64898/2026.04.07.717107

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

KRAS inhibition is an effective therapy for appendiceal adenocarcinomaDOI 10.64898/2026.04.07.717107Read

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancerSemantic proximity Read

An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Semantic proximity Read

Uncovering molecular pathways in appendiceal cancer: A comprehensive characterization for precision oncology.Semantic proximity Read

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity Read

Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.Semantic proximity Read

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Semantic proximity Read